HLA class II‐associated genetic susceptibility in multiple sclerosis: A critical evaluation

Tissue Antigens

Volumn 38, Issue 2, 1991, Pages 1-15

  Olerup, Olle ^a,b   Hillert, Jan ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Department of Clinical Immunology ^*

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

genetic susceptibility; HLA D anti gens; HLA DP; HLA DQ HLA DR; multiple sclerosis; polymerase chain reaction; primarily chronic progressive multiple sclerosis; relapsing remitting multiple sclerosis; restriction fragment length polymorphism

Indexed keywords

HLA ANTIGEN CLASS 2;

CONTROLLED STUDY; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW;

DISEASE SUSCEPTIBILITY; GENES, MHC CLASS II; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMAN; MULTIPLE SCLEROSIS; SUPPORT, NON-U.S. GOV'T;

EID: 0025767289     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1991.tb02029.x     Document Type: Review

References (89)

1. Power of the affected‐sib‐pair method to detect disease susceptibility loci of small effect: An application to multiple sclerosis
2. A population‐based study of multiple sclerosis in twins
3. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course
4. Multiple sclerosis
5. HLA‐Linked and unlinked determinants of multiple sclerosis
6. Multiple sclerosis in French Canadians: Evidence for HLA class I1 susceptibility and resistance genes
7. Primarily chronic progressive and relapsing/remitting multiple sclerosis: Two immunogenetically distinct disease entities
8. Patients with multiple sclerosis carry DQB1 genes which encode shared polymorphic amino acid sequences
9. HLA‐DQA1 and HLA‐DQB1 genes may jointly determine susceptibity to develop multiple sclerosis
10. HLA class II genes in chronic progressive and in relapsing/remitting multiple sclerosis
11. Problems of experimental trials of therapy in multiple sclerosis: Report by the panel of the evaluation of experimental trials of therapy in multiple sclerosis
12. HLA‐D region associated MS‐susceptibility genes may be located telomeric to the HLA‐DP subregion
13. Individuals with HLA‐DR blank alleles display well‐known DR‐DQ RFLPs
14. Nomenclature for factors of the HLA system, 1989
15. HLA‐DR‐DQ haplotypes defined by restriction fragment length analysis: Correlation to serology
16. A DNA‐RFLP typing system which positively identifies serologically well‐defined and ill‐defined HLA‐DR and ‐DQ alleles, including DRw10
17. HLA class II genes: typing by DNA analysis
18. Restriction fragment length polymorphism of the HLA‐DP subregion and correlation to HLA‐DP phenotypes
19. Restriction fragment length polymorphism (RFLP) of a “new” HLA‐DP specificity, CDP‐HEI
20. DP RFLP studies of the 72 core cell lines selected for the Southern blot protocol
21. Sequence analysis of the HLA‐DR4BI subtypes: Additional first domain variability is detected by oligonucleotide hybridization and nucleotide sequencing
22. HLA‐DQβ gene contributes to susceptibility and resistance to insulin‐dependent diabetes mellitus
23. The amino acid at position 57 of the HLA‐DQβ chain and susceptibility to develop insulin‐dependent diabetes mellitus
24. Relative predispositional effects (RPEs) of marker alleles with disease: HLA‐DR alleles and Graves disease
25. On estimating the relation between blood group and disease
26. The data and statistical analysis
27. Investigation of the mode of inheritance of the HLA associated diseases by the method of antigen genotype frequencies among diseases individuals
28. Genomic HLA‐typing by RFLP‐analysis using DRβ and DQβ cDNA probes reveals normal DR‐DQ linkages in patients with multiple sclerosis
29. HLA‐DR and ‐DQ DNA genotyping in multiple sclerosis patients in Northern Ireland
30. Multiple sclerosis and HLA class II susceptibility and resistance genes
31. Increased frequency of HLA‐DRw2 and DRw3 in multiple sclerosis
32. HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes
33. HLA associations with multiple sclerosis in Sicily and Malta
34. Different B lymphocyte alloantigens associated with multiple sclerosis in Arabs and North Europeans
35. Sardinian multiple sclerosis is associated with HLA‐DR4
36. HLA and Japanese MS
37. Immunogenetic profile of multiple sclerosis in Mexicans
38. HLA‐DRβ, ‐DQα and ‐DQβ restriction fragment length polymorphisrns in multiple sclerosis
39. Letter
40. Multiple sclerosis in north‐east Scotland: An association with DQw1
41. HLA and multiple sclerosis in south east Wales
42. Sex distribution, age of onset and HLA profiles in two types of multiple sclerosis: A role for sex hormones and microbial infections in the development of autoimmunity
43. HLA genetic factors involved in familial MS: RFLP study defines a particular DQw1 subtype associated with the disease
44. An allelic cluster of DQα restriction fragments is associated with multiple sclerosis: Evidence that a second haplotype may influence disease susceptibility
45. Linkage disequilibrium between the HLA‐DQA2 alleles and the HLA‐DR/DQ complex
46. Association of class II HLA‐DQβ chain DNA restriction fragments with multiple sclerosis
47. Association between the lack of HLA‐DQw6 and the low incidence of multiple sclerosis in Hungarian Gypsies
48. Allelic sequence variation of the HLA‐DQ loci: Relationship to serology and to insulin‐dependent diabetes susceptibility
49. Genetic controls of autoimmunity in Type I diabetes
50. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis
51. HLA‐DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II regon
52. Different amino acids at position 57 of the HLA‐DQβ chain associated with susceptibility and resistance to IgA deficiency
53. HLA antigens in black American patients with multiple sclerosis
54. Oligonucleotide dot‐blot analysis of HLA‐DQβ alleles associated with multiple sclerosis
55. Influence of allelic polymorphism on the assembly and surface expression of class II MHC (Ia) molecules
56. Predominant role of amino‐terminal sequences in dictating efficiency of class II major histocompatibility complex αβ dimer expression
57. Allelic polymorphism and transassociation of molecules encoded by the HLA‐DQ subregion
58. HLA‐A, B, C and DR antigens in psoriasis
59. Transcom‐plementation of HLA genes in IDDM. HLA‐DQ α‐ and β‐chains produce hybrid molecules in DR3/4 heterozygotes
60. A combination of HLA‐DQβ ASp57‐negative and HLA‐DQα ARg52 confers susceptibility to insulin‐dependent diabetes mellitus
61. Distribution of HLA‐DRBI, ‐DQA1 and ‐DQB1 alleles and DQA1‐DQB1 genotypes among Norwegian patients with insulin‐dependent diabetes mellitus
62. Evidence for a primary association of celiac disease to a particular HLA‐DQ α/β heterodimer
63. Allelic diversification of the class II DQB locus of the mammalian major histocompatibility complex
64. A genetically controlled pairing anomaly between HLA‐DQα and HLA‐DQβ chains
65. Restricted assembly of MHC class II molecules in transgenic mice
66. T lymphocyte recognition of a celiac disease‐associated cis‐ or trans‐encoded HLA‐DQ α/β heterodimer
67. HLA–DP antigens are involved in the susceptibility to multiple sclerosis
68. HLA‐DP antigens and HTLV‐I antibody status among Japanese with multiple sclerosis: Evidence for an increased frequency of HLA‐DPw4
69. HLA‐DPβ and susceptibility to multiple sclerosis: An analysis of Caucasoid and Japanese patient populations
70. Multiple sclerosis — more than one disease
71. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients
72. Clinical parameters and intrathecal IgG synthesis as prognostic features in multiple sclerosis. Part I
73. Prognostic indicators in multiple sclerosis
74. Long‐term immunosuppressive treatment with azathioprine in multiple sclerosis
75. A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow up
76. Pathogenesis of progressive multiple sclerosis
77. Allelic variation in the DR subregion of the human major histocompatibility complex
78. Structural and functional variability among DQβ alleles of DR2 subtypes
79. The germline repertoire of T cell receptor β‐chain genes in patients with chronic progressive multiple sclerosis
80. T‐cell receptor Vα and Cα alleles associated with multiple sclerosis and myasthenia gravis
81. No association with germline T cell receptor β‐chain gene alleles or haplotypes in Swedish patients with multiple sclerosis
82. The germline repertoire of T‐cell receptor β chain genes in patients with relapsing/remitting multiple sclerosis or optic neuritis
83. T cell receptor a chain germline gene polymorphism in multiple sclerosis
84. Speculations on the mechanisms of HLA associations with autoimmune diseases and the specificity of “autoreactive” T lymphocytes
85. Distribution of HLA‐SB antigens in multiple sclerosis